Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 676 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Steatoses Clear all
Terminated Phase 1Phase 2 Interventional

Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

NCT03511365
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018, Interleukin-17 MeSH Descriptor Data 2018
Interventions
Probiotic Formulation VSL#3
Biological
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

NCT03513523
View directory record Official record
Conditions
Fatty Liver
Interventions
Group 1 NRPT, Group 2 NRPT, Group 3 Placebo
Dietary Supplement · Other
Lead sponsor
Elysium Health
Industry
Eligibility
18 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
Hialeah, Florida • Lake Worth, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
81
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

NCT02316717
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
IMM-124E, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
17
States / cities
Chula Vista, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Sep 30, 2026, 9:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196, Placebo, Liver Biopsy
Drug · Procedure
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
90
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03400163
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

NCT04521114
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Placebo, leronlimab 700 mg, leronlimab 350 mg
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Coronado, California • Maitland, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 30, 2026, 9:35 AM EDT
Not listed No phase listed Observational

Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

NCT02124577
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Not applicable Interventional

The Effect of Time-restricted Eating on Liver Metabolism

NCT04997486
View directory record Official record
Conditions
NAFLD, Obesity, Nutritional and Metabolic Diseases
Interventions
Time restricted eating
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 30, 2026, 9:35 AM EDT
Terminated Phase 2 Interventional

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT03676231
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SGM-1019, Placebo
Drug
Lead sponsor
Second Genome
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

NCT01963845
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

NCT02654002
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of High-Intensity Interval Training Exercise in Adolescents With Hepatosteatosis

NCT04342390
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Insulin Resistance, High Intensity Interval Training, Childhood Obesity
Interventions
High-Intensity Interval Training (HIIT)
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
13 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Not applicable Interventional Results available

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

NCT03717935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
Essential Amino Acid (EAA) Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589
View directory record Official record
Conditions
HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

NCT03998514
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
Drug
Lead sponsor
CohBar, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 30, 2026, 9:35 AM EDT
Recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784
View directory record Official record
Conditions
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Sep 30, 2026, 9:35 AM EDT
Not listed No phase listed Observational

Copeptin and Nonalcoholic Fatty Liver Disease

NCT03254563
View directory record Official record
Conditions
NAFLD
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 30, 2026, 9:35 AM EDT
Recruiting Phase 2 Interventional

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

NCT04501406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

NCT04857606
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
AMG 609, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • Chula Vista, California • Montclair, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 30, 2026, 9:35 AM EDT
Active, not recruiting Not applicable Interventional

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

NCT06735924
View directory record Official record
Conditions
MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Low-oxalate fixed diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

NCT04845646
View directory record Official record
Conditions
Healthy, NAFLD
Interventions
ASC41, Itraconazole, Phenytoin
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Sep 30, 2026, 9:35 AM EDT
Completed Not applicable Interventional

NASH AMPK Exercise Dosing (AMPED) Trial

NCT04987879
View directory record Official record
Conditions
NAFLD
Interventions
Exercise
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 30, 2026, 9:35 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Guerbet Liver Fibrosis

NCT06703450
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 30, 2026, 9:35 AM EDT